A new CEOs at Merck & Co and Pfizer – People on the move
The board of directors at Pfizer has elected Ian Read as CEO after Jeffrey Kindler retired. Read is currently head of global biopharm operations at Pfizer. The resignation of Kindler was unexpected.
Kenneth Frazier has been elected CEO of Merck & Co and will replace Richard Clark in this role on January 1. Frazier, who is president of Merck, has also been elected as a member of the board. Clark will continue as chairman of the board after stepping down as CEO in January.
Lupin has appointed Georg Salm-Reifferscheidt-Raitz as manager director of its German unit, Hormosan Pharma Gmbh. Raitz has 20 years in the German and Austrian pharma sector and has worked as a business consultant at PricewaterhouseCoopers.
Michael Pennington is the new chief technical officer at Peptides International, giving him responsibility for research, production and quality control. Pennington joins Peptides from Bachem Bioscience.
InSite Vision has named Timothy Ruane as CEO and elected him to the board of directors. Louis Drapeau, interim-CEO, will continue to work as chief financial officer. Ruane is the former CEO of Tekmira Pharmaceuticals.
Pam Tyler, purchasing manager at DPT Laboratories, has been elected to serve the executive committee of the board of directors at the Drug, Chemical and Associated Technologies Association (DCAT) for 2011.
Tyler, who has worked at DPT for more than 10 years, will serve DCAT as vice president of the contract formulation, fill, finish and packaging industry segment.
IGI Laboratories has appointed Bhaskar Chaudhuri to its board of directors. Chaudhuri has more than 20 years of experience in pharma management and R&D at companies including Valeant, Bertek and Mylan Laboratories.
Sandra Luciano has joined the healthcare packaging division of Winpak Heat Seal. Luciano has more than 15 years of pharma and healthcare packaging experience from working at Amcor Flexibles, Rexam and Sharp.
